Overview

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Status:
Not yet recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and new glucose tracer Me-4FDG designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

American Cancer Society, Inc.
Lungevity Foundation